Journal
CANCERS
Volume 11, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/cancers11101572
Keywords
endometrial cancer; diagnostic biomarkers; proteomics; mass spectrometry
Categories
Funding
- Cancer Research UK (CRUK) Manchester Cancer Research Centre Clinical Research Fellowship [C147/A25254]
- National Institute of Health Research Manchester Biomedical Research Centre [IS-BRC-1215-20007]
- Medical Research Council [MR/M008959/1]
- CRUK Manchester Major Centre award [C147/A25254]
- Wellcome Trust Manchester Translational Informatics Training Scheme
- MRC [MR/M008959/1] Funding Source: UKRI
Ask authors/readers for more resources
Endometrial cancer is the leading gynaecological malignancy in the western world and its incidence is rising in tandem with the global epidemic of obesity. Early diagnosis is key to improving survival, which at 5 years is less than 20% in advanced disease and over 90% in early-stage disease. As yet, there are no validated biological markers for its early detection. Advances in high-throughput technologies and machine learning techniques now offer unique and promising perspectives for biomarker discovery, especially through the integration of genomic, transcriptomic, proteomic, metabolomic and imaging data. Because the proteome closely mirrors the dynamic state of cells, tissues and organisms, proteomics has great potential to deliver clinically relevant biomarkers for cancer diagnosis. In this review, we present the current progress in endometrial cancer diagnostic biomarker discovery using proteomics. We describe the various mass spectrometry-based approaches and highlight the challenges inherent in biomarker discovery studies. We suggest novel strategies for endometrial cancer detection exploiting biologically important protein biomarkers and set the scene for future directions in endometrial cancer biomarker research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available